Formycon AG announced the first enrollment in the Phase III "Lotus" study comparing FYB206/pembrolizumab with leading cancer drug Keytruda for safety and efficacy.

Celldex Therapeutics announces successful findings from Phase 2 trial of Barzolvolimab for chronic inducible urticaria.

Roche disclosed today that the European Commission has given the green light to Vabysmo® (faricimab) .

Galderma has successfully completed the European decentralized procedure, leading to a favorable decision for RelfydessTM.

Compugen has announced that the U.S. Food and Drug Administration has approved the investigational new drug application to begin a Phase 1 trial for COM503.

Alpha Cognition has reported that the U.S. Food and Drug Administration has given the green light to ZUNVEYL® (benzgalantamine).

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia.

CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer.

According to the agreement, Immunome has obtained exclusive rights to a collection of antibodies directed at an undisclosed target.

European Medicines Agency Rejects Eisai's Lecanemab for Alzheimer’s Treatment.

AbbVie revealed that the European Commission has granted approval for SKYRIZI(risankizumab) to be used in adult patients suffering from moderately to severely active ulcerative colitis.

Chemomab Therapeutics Announces Positive Results in Phase 2 Study: CM-101 Demonstrates Anti-Fibrotic, Anti-Inflammatory, and Anti-Cholestatic Effects in Primary Sclerosing Cholangitis.